Literature DB >> 21328321

Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose.

Michael J Gramer1, Jackie J Eckblad, Ruth Donahue, Joseph Brown, Carrie Shultz, Kent Vickerman, Patrick Priem, Ewald T J van den Bremer, Jolanda Gerritsen, Patrick H C van Berkel.   

Abstract

Through process transfer and optimization for increased antibody production to 3 g/L for a GS-CHO cell line, an undesirable drop in antibody Fc galactosylation was observed. Uridine (U), manganese chloride (M), and galactose (G), constituents involved in the intracellular galactosylation process, were evaluated in 2-L bioreactors for their potential to specifically increase antibody galactosylation. These components were placed in the feed medium at proportionally increasing concentrations from 0 to 20 × UMG, where a 1× concentration of U was 1 mM, a 1× concentration of M was 0.002 mM, and a 1× concentration of G was 5 mM. Antibody galactosylation increased rapidly from 3% at 0× UMG up to 21% at 8× UMG and then more slowly to 23% at 20× UMG. The increase was primarily due to a shift from G0F to G1F, with minimal impact on other glycoforms or product quality attributes. Cell culture performance was largely not impacted by addition of up to 20× UMG except for suppression of glucose consumption and lactate production at 16 and 20× UMG and a slight drop in antibody concentration at 20× UMG. Higher accumulation of free galactose in the medium was observed at 8× UMG and above, coincident with achieving the plateau of maximal galactosylation. A concentration of 4× UMG resulted in achieving the target of 18% galactosylation at 2-L scale, a result that was reproduced in a 1,000-L run. Follow-up studies to evaluate the addition of each component individually up to 12× concentration revealed that the effect was synergistic; the combination of all three components gave a higher level of galactosylation than addition of the each effect independently. The approach was found generally useful since a second cell line responded similarly, with an increase in galactosylation from 5% to 29% from 0 to 8× UMG and no further increase or impact on culture performance up to 12× UMG. These results demonstrate a useful approach to provide exact and specific control of antibody galactosylation through manipulation of the concentrations of uridine, manganese chloride, and galactose in the cell culture medium.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328321     DOI: 10.1002/bit.23075

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  27 in total

1.  Galactosylation variations in marketed therapeutic antibodies.

Authors:  T Shantha Raju; Robert E Jordan
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Galactose supplementation enhance sialylation of recombinant Fc-fusion protein in CHO cell: an insight into the role of galactosylation in sialylation.

Authors:  Jintao Liu; Jie Wang; Li Fan; Xinning Chen; Dongdong Hu; Xiancun Deng; H Fai Poon; Haibin Wang; Xuping Liu; Wen-Song Tan
Journal:  World J Microbiol Biotechnol       Date:  2015-05-01       Impact factor: 3.312

Review 3.  Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.

Authors:  Austin Wt Chiang; Shangzhong Li; Philipp N Spahn; Anne Richelle; Chih-Chung Kuo; Mojtaba Samoudi; Nathan E Lewis
Journal:  Curr Opin Struct Biol       Date:  2016-09-14       Impact factor: 6.809

4.  The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside.

Authors:  Yasuhiro Takagi; Takuya Kikuchi; Ryuta Wada; Takeshi Omasa
Journal:  Cytotechnology       Date:  2017-03-02       Impact factor: 2.058

5.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  A simultaneous assessment metric for MAb quantity and glycan quality.

Authors:  Gerald Drouillard; Gordon Hayward; Julie Vale; Roshni Dutton
Journal:  Cytotechnology       Date:  2016-08-09       Impact factor: 2.058

7.  Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.

Authors:  Xiaoyu Yang; Sunnie Myung Kim; Richard Ruzanski; Yuetian Chen; Sarath Moses; Wai Lam Ling; Xiaojuan Li; Shao-Chun Wang; Huijuan Li; Alexandre Ambrogelly; Daisy Richardson; Mohammed Shameem
Journal:  MAbs       Date:  2016-04-15       Impact factor: 5.857

8.  Predictive glycoengineering of biosimilars using a Markov chain glycosylation model.

Authors:  Philipp N Spahn; Anders H Hansen; Stefan Kol; Bjørn G Voldborg; Nathan E Lewis
Journal:  Biotechnol J       Date:  2016-12-28       Impact factor: 4.677

9.  Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates.

Authors:  Feng Tang; Lai-Xi Wang; Wei Huang
Journal:  Nat Protoc       Date:  2017-07-27       Impact factor: 13.491

10.  Comprehensive manipulation of glycosylation profiles across development scales.

Authors:  Sven Loebrich; Elisa Clark; Kristina Ladd; Stefani Takahashi; Anna Brousseau; Seth Kitchener; Robert Herbst; Thomas Ryll
Journal:  MAbs       Date:  2018-10-22       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.